On September 16, 2025 CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), reported it has been selected for a poster and an oral presentation at the upcoming AACR (Free AACR Whitepaper) Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity, taking place September 24 to 27, 2025, in Montreal, Canada (Press release, CytoDyn, SEP 16, 2025, View Source [SID1234655996]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Richard Pestell, M.D., Ph.D., FRCP, AO, Lead Consultant in Preclinical and Clinical Oncology at CytoDyn, will deliver a podium presentation on the effects of leronlimab on metastatic triple-negative breast cancer.
"We are encouraged by these findings, which suggest that leronlimab may convert ‘cold’ tumors into ‘hot’ ones, making them more responsive to checkpoint inhibitors in diseases like metastatic triple-negative breast cancer, an aggressive disease with substantial unmet need," said Dr. Pestell, "The results of this research will also help to shed light on an underlying mechanism of action for leronlimab with potential broad applicability for solid tumors with limited treatment options."
Details of the oral and poster presentations are as follows:
Abstract Title:
CCR5 inhibition with leronlimab is associated with enhanced PD-L1 expression, ICI response, and long‑term survival in metastatic TNBC
Presenter:
Richard Pestell, M.D., Ph.D., FRCP AO, Lead Consultant in Preclinical and Clinical Oncology at CytoDyn
Poster presentation:
September 26, 2025, 6:30 p.m. – 8:30 p.m. EDT
Podium/speaking presentation:
September 27, 2025, 10:25 a.m. – 10:40 a.m. EDT